Screener
CytomX Therapeutics CTMX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Accounts payable | 638 | (853) |
| Accrued liabilities and other long-term liabilities | (261) | (3,209) |
| Deferred revenue | 26,223 | (61,772) |
| Net cash used in operating activities | (43,617) | (36,796) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | — | (146) |
| Purchases of short-term investments | (311,824) | (128,618) |
| Maturities of short-term investments | 125,000 | 83,000 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's operating cash flow?
- CytomX Therapeutics (CTMX) reported operating cash flow of -$18.07M in Q2 2026.
- How has CytomX Therapeutics's operating cash flow changed year-over-year?
- CytomX Therapeutics's operating cash flow decreased by 14.7% year-over-year, from -$15.75M to -$18.07M.
- What is the long-term trend for CytomX Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), CytomX Therapeutics's operating cash flow has grown at a -10.7% compound annual growth rate (CAGR), from -$119.03M to -$75.59M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about CytomX Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude